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KAJIAN ANTI-TUMOR SCOPOLETIN DAN RUBBING-MERCAPTO-NITRILE 
DARI NICOTIANA GLAUCA 
ABSTRAK 
Nicotiana glauca (Solanaceae) telah digunakan secara tradisional untuk merawat 
jangkitan dan kanser. Tumbuhan ini dilaporkan kaya dengan komponen–komponen yang 
baik untuk kesihatan. Dalam kajian ini, dua komponen anti-tumor daripada ekstrak n-
heksana N. glauca telah berjaya diasingkan, iaitu scopoletin dan satu komponen baru, 
Rubbing-Mercapto-Nitrile (RMN). Pengasingan scopoletin berpandukan aktiviti anti-
angiogenesis telah dijalankan menggunakan ekstrak daripada batang N. glauca. Aktiviti 
anti-angiogenesis scopoletin dikaji menggunakan model–model angiogenesis secara ex vivo 
dan in vivo. Keberkesanan anti-tumorigenik scopoletin dikaji menggunakan xenograf tumor 
kolorektal manusia pada mencit nude atimik. Scopoletin menyebabkan perencatan 
signifikan dalam percambahan salur mikro pada eksplan aortik tikus dengan nilai kepekatan 
perencatan 50% adalah 34 µg/ml. Scopoletin (100 dan 200 mg/kg) merencat dengan 
berkesan vaskularisasi plak matrigel yang diimplan pada mencit nude, masing–masing 
sebanyak 59.72% dan 89.4%. Dalam model xenograf tumor, scopolectin menunjukkan 
potensi perencatan pertumbuhan tumor (34.2% dan 94.7%, masing–masing pada kepekatan 
100 dan 200 mg/kg). Kajian histologi tumor menunjukkan penurunan drastik dalam proses 
vaskularisasi. Secara in silico, scopoletin menunjukkan afiniti ligan yang kuat dan daya 
ikatan yang tinggi terhadap faktor–faktor angiogenik berikut: protin kinase (ERK1), faktor 
pertumbuhan endothelial vascular-A (VEGF-A), dan faktor pertumbuhan fibroblast-2 
(FGF-2). Seterusnya, kompaun baru yang dikenali sebagai Rubbing-Mercapto-Nitrile 
(RMN) juga telah diasingkan dari N. glauca dan dikaji dengan lebih lanjut. RMN 
xxi 
 
mempunyai kesan sitotoksik yang poten dan terpilih terhadap sel–sel kanser kolorektal 
HCT-116. Kompaun ini meransang proses apoptosis di dalam tisu neoplastik dengan nilai 
indeks terpilih yang tinggi (SI = 4.3). Keadaan ini menyebabkan berlakunya kondensasi 
nuklear, pereputan kromatin, dan kerosakan pada membran mitokondria. RMN juga 
menyebabkan penurunan pengawalaturan laluan isyarat bagi TGF dan HIF dan kenaikan 
pengawalaturan pada laluan–laluan isyarat WNT, NOTCH, NF-κB, ERK, P53, dan JNK 
secara in vitro. Secara keseluruhannya, dua komponen anti-kanser telah diasingkan dan 
dikenalpasti daripada N. glauca dan aktiviti anti-tumor scopoletin telah disahkan secara ex 
vivo dan in vivo dan aktiviti RMN telah dipastikan secara in vitro beserta dengan target 
molekular. 
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ANTI-TUMOR STUDY OF SCOPOLETIN AND RUBBING-MERCAPTO-NITRILE 
FROM NICOTIANA GLAUCA 
ABSTRACT 
Nicotiana glauca (Solanaceae) has been traditionally used as a folk remedy to treat 
infections and cancer. It has been reported as a rich source of beneficial phytochemicals. In 
the present study, two anti-tumor compounds derived from n-hexane extract of N. glauca 
namely scopoletin and, a novel compound, Rubbing-Mercapto-Nitrile (RMN) have been 
isolated. Antiangiogenesis-guided isolation of scopoletin was conducted using an extract 
from the stem of N. glauca. The anti-angiogenic activity of scopoletin was investigated 
using ex vivo and in vivo angiogenesis models. The antitumorigenic efficacy of scopoletin 
was studied in human colorectal tumor xenografts using athymic nude mice. Scopoletin 
caused significant suppression of microvessel sprouting in rat aortic explants with IC50 of 
34 µg/ml. Scopoletin (100 and 200 mg/kg) strongly inhibited (59.72% and 89.4%, 
respectively) vascularization in matrigel plugs implanted in nude mice. In a tumor 
xenograft model, scopoletin showed potent inhibition of tumor growth (34.2% and 94.7% 
at 100 and 200 mg/kg, respectively). Tumor histology reveals a drastic decline of 
vascularization. In silico studies suggest that scopoletin strongly inhibit protein kinase 
(ERK1), vascular endothelial growth factor A (VEGF-A), and fibroblast growth factor 2 
(FGF-2). A novel anti-cancer compound Rubbing-Mercapto-Nitrile (RMN) was also 
isolated from N. glauca and characterized. RMN has potent but selective cytotoxic activity 
towards HCT-116 colorectal cancer cells. The compound stimulates strong apoptosis in the 
neoplastic tissue with a high selective index (SI = 4.3). It causes nuclear condensation, 
chromatin degradation, and damage to the mitochondrial membrane. RMN also causes 
xxiii 
 
down-regulation of the TGF and HIF signaling pathways, and up-regulation of the WNT, 
NOTCH, NF-κB, ERK, P53, and JNK signaling pathways in vitro. Overall, in this study, 
two anticancer compounds were isolated and identified from N. glauca and the antitumor 
activity of Scopoletin was verified ex vivo and in vivo and the RMN activity was confirmed 
in vitro with their molecular targets identified.  
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CHAPTER ONE: INTRODUCTION 
1.1.Overview of cancer 
Over 200 types of cancer that harm the human body have been recognized. Cancer is 
the second leading cause of death worldwide, surpassed only by heart disease. It is reported 
in all ages; and one in three people may contract this disease in his or her lifetime. 
Unfortunately, this ratio is expected to increase to 55% by 2020 (Cerveira & Bizarro, 
2012). Cancer is characterized by excessive and uncontrolled cellular growth followed by 
local tissue invasion and tumor metastasis (Chabner, 2006). A tumor may be comprised of 
either normal cells (benign, hyperplasia) or abnormal cells (dysplasia, malignant), probably 
due to genetic mutation. Tumorigenesis occurs when there is dysregulation in more than six 
cellular pathways, leading to prolonged angiogenesis, irresponsiveness to anti-growth 
signals, evasion of programmed cell death, continuous growth independently of 
proliferation signals, lack of apoptosis, and metastasis. A variety of factors may lead to an 
increase in the risk of cancer. Some may be genetically linked, resulting in irregular control 
of cell-cycle checkpoints, hyper-activation of oncogenes, and inhibition of tumor-
suppressing genes. Environmental factors comprise absence of physical activity, oxidative 
stress, radiation, smoking, and obesity (Hanahan & Weinberg, 2000; Johnson et al., 1996) 
The main methods of cancer treatment currently applied are: surgery, chemotherapy and 
radiotherapy. Traditionally, cancer is diagnosed using available medical imaging 
techniques and biochemical screening tests (Shewach & Kuchta, 2009). 
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1.2. The incidence and mortality of cancer  
Cancer has become one of the most common health problems in the world. In 2012, 
more than 14 million new cases were reported and about 8.2% resulted in death (Ferlay et 
al., 2014). The highest incidence of cancer among men is that of prostate cancer, which 
accounts for 25% of all newly diagnosed cancer cases in men. On the other hand, breast 
cancer represents 27% of all newly diagnosed cancer cases in women and is followed by 
lung and colon cancers respectively (A. Jemal et al., 2009). In the developed countries, 
including North America, Japan, the European countries, Russia, Australia and New 
Zealand, the number of new cases is less than that reported in developing countries of lower 
resources (5,600,000 vs. 7,100,000 cases  respectively) (Boffetta et al., 2014). In addition , 
the cancer survival  rate tends to be lower in the developing countries; and that is most 
likely because of lacking educational facilities and financial resources, limited access to 
health services, and the kind of dietary intake (Jemal et al., 2011). The World Health 
Organization (WHO) has estimated that the number of people diagnosed with cancer will 
rise in 2030 by 21.4 million. 
  Based on the latest Health Facts released by the Malaysian Ministry of Health 
(MoH) in 2013, cancer is one of the top-ten causes of hospitalization and one of the top-
five causes of death in Malaysia. The incidence of cancer increased from the annual 32,000 
new cases in 2008 to about 37,000 in 2012. Mortality due to cancer stood at 20,100 deaths 
in 2008, and has increased to 21,700 deaths in 2012. 
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1.3.The differences between normal and cancer cells 
What makes a cancer cell different is its abnormal behavior and inability to react 
properly under a whole set of conditions (Iyer et al., 2009). Cancer cells have many distinct 
characteristics compared with the normal ones, some of which are well understood, 
whereas others are still under research. These differences pave the way for researchers to 
discover new treatments which target cancer cells and spare the normal ones (Polyak & 
Weinberg, 2009). First, normal cells are controlled by the tumor suppressor genes, which 
control the growth of cells by sending death signals when the cells are damaged or too old; 
and any mutation in these genes may result in an uncontrolled cancer cell growth. Second, a 
normal cell responds to signals from the neighboring cells to stop its growth when such is 
needed. In contrast, malignant cells ignore these signals and move outward from the focus 
of the origin of the neoplasm (Abercrombie & Ambrose, 1962). Third, cancer is an age-
related disease in organisms with renewable tissues; and it is widely acceptable that age-
related degenerative diseases generally trigger a loss of cell function. As a result, a cancer 
cell does not perform the function compared with a normal cell. For example, in leukemia, 
the cancerous white cells are not functional and cannot treat an infection despite the very 
high count of white blood cells. And that also applies to cancerous thyroid cells, which 
cannot produce thyroid hormones like the normal ones (Campisi & Yaswen, 2009). Fourth, 
cancer cells are not limited by oxidative metabolism as they produce most of their energy in 
the absence of oxygen, unlike normal cells, which require oxygen to complete the krebs 
cycle (Moreno-Sanchez et al., 2007). Fifth, normal cell populations are mortal, which 
distinguishes them from cancerous cells which have an immortality property i.e., they don’t 
have a life span (Hayflick, 2000). Researchers addressed the causes and mechanisms 
underlying this phenomenon and they concluded that the limitations in the growth cycles of 
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normal cells are attributable to the length of their telomeres (long strands at the end of the 
DNA). As a cell divides multiple times, the telomeres get shorter and shorter till the cell 
dies. However, in the event of cancer, the cells renew their telomeres so that they can 
continue to divide endlessly–basically becoming immortal (Hayflick, 2000). Sixth, cancer 
cells are “undifferentiated” i.e., they don’t have the ability to differentiate into specialized 
mature cells, whereas normal cells are “well-differentiated” (Edge & Compton, 2010). The 
term ‘differentiation’ is also used to provide information for cancer assessment. It is an 
indicator that provides information on the speed of growth and the spreading of a tumor. 
Hence, the ‘degree of differentiation’ is associated with a tumor’s developmental process, 
whereby it gives information on cancer progression and aggressiveness. The closer to 
normal (differentiated) a cancer cell appears,  the lower the grade is, and the less aggressive 
the tumor is considered (Jögi et al., 2012). Cancer cells are characterized by genomic 
instability, which is proportional to the number of chromosomal abnormalities resulting 
from mutations in the DNA-repair genes. The greater this number is, the higher the stage of 
cancer should be (Negrini et al., 2010). Other contributing factors are the decrease and 
increase in the oligonucleotide repeats present in microsatellite sequences (Leach et al., 
1993), and the increase in the number of base-pair mutations (Al-Tassan et al., 2002; Fishel 
et al., 1993). On the other hand, normal cells have intact, normal DNA; and a normal 
number of chromosomes (Negrini et al., 2010). Finally, cancer cells have the ability to 
spread from a primary site (the origin of the cancer) to a distant organ in a process called 
“Metastasis”, which consists of many distinct sequential steps  (Table 1.1) (Figure 1.2) 
(Judah Folkman, 2002b) summarized as follow: A cancer cell is shed from the primary 
tumor into the body’s circulatory or lymphatic systems, a phenomenon known as 
intravasation. The cells must then survive in the circulation till they are arrested in an 
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organ. This process is referred to as extravasation, in which the cells go from the circulation 
into a surrounding tissue where they would maintain their growth rate and undergo pre-
angiogenic micrometastasis (Moreno-Sanchez et al., 2007). Breast and prostate cancers 
often metastasize to the bones (Woodhouse, Chuaqui, & Liotta, 1997) (Woodhouse et al., 
1997). On the other hand, normal breast and prostate cells cannot undergo this process 
(Chambers et al., 2002). 
Table 1.1: The differences between normal and cancer cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proper (-) Improper (+) Normal cancer 
Response to stop signals - + 
Response to death signals - + 
Response to aging signals - + 
Growth - + 
Differentiation - + 
Recruitment of food  - + 
Movement  - + 
Immortality  - + 
Genomic instability - + 
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Figure 1.1: Forming tumor among normal cells  
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Figure 1.2: Metastasis of a cancer cell    
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1.4.The molecular biology of cancer 
Cancer, in essence, is a heterogeneous disease caused by the accumulation of many 
somatic mutations. Each single gene defect “causes” cancer, because each mutation drives a 
wave of cellular proliferation, tumor size exaggeration, disorganization and malignancy (B. 
Vogelstein & Kinzler, 1993). The majority of these mutations are acquired and “not 
inherited”. They casually arise as consequences to damage at the genome level. Such 
damage could result from an endogenous process, like a mistake occurring during DNA 
replication; an attack by free radicals produced during metabolism; or the instability of 
certain DNA bases. It might also involve exogenous agents, such as UV and ionizing 
radiations, or chemical carcinogens (Bertram, 2000). Tumors show different behaviors in 
different tissues. For example ,cancer cells of the pancreas are more aggressive than those 
in the prostate (Pedraza-Fariña, 2006). The mechanism through which cells transform to 
cancer is incompletely understood. However, it is assumed that it implicates many factors 
which disturb the balance between cell proliferation and cell death, leading to abnormal cell 
differentiation and proliferation. A cancer is believed to take place through the activation of 
oncogenes, or the downregultion of the tumor-suppressor genes; which are linked to signal 
transduction pathways (Cerveira & Bizarro, 2012). Oncogene activation from Proto-
oncogenes could be the result of gene amplification or chromosomal translocations. It 
promotes cell growth and proliferation analogous to a car which still moves forward even 
after the driver has removed his foot off the pedal. Tumor-suppressor genes work in the 
opposite direction as they attenuate cell growth processes. Inactivation of these genes could 
be the result of missense mutations, mutations resulting in truncated proteins, or epigenetic 
silencing. It is analogous to having dysfunctional brakes in an automobile preventing the 
car from stopping even when the driver tries to engage them (Vogelstein & Kinzler, 2004).  
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Five major pathways must be activated/inactivated in the process of cell genesis for 
a normal cell to transform into a cancer cell (Bertram, 2000), contributing to the 
development of independence from growth stimulatory signals; development of a refractory 
state to growth inhibitory signals; development of resistance to programmed cell death, 
apoptosis; development of an infinite proliferative capacity i.e., overcoming cellular 
senescence; and development of an angiogenic potential i.e., the capacity to form new 
blood vessels and capillaries. 
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Table 1.2 Cancer predisposition genes (Vogelstein & Kinzler, 2004) 
Gene synonym(s) Syndrome 
Hereditary 
pattern 
Pathway 
Major heredity 
tumor types 
Tumor-suppressor genes 
APC FAP Dominant APC 
Colon, thyroidal, 
stomach, intestinal 
AXIN2 
Attenuated 
polyposis 
Dominant APC Colon 
CDH1 (E-cadherin) 
Familial 
gastric 
carcinoma 
Dominant APC Stomach 
GPC3 
Simpson-
Golabi-Behmel 
syndrome 
 
X-linked APC Embryonal 
CYLD 
Familial 
cylindromatosi
s 
Dominant APOP Pilotrichomas 
EXT1,2 
Hereditary 
multiple 
exostoses 
 
Dominant GLI Bone 
PTCH 
Gorlin 
syndrome 
Dominant GLI 
Skin, 
medulloblastoma 
 
SUFU 
Medulloblasto-
ma 
predisposition 
 
Dominant GLI 
Skin, 
medulloblastoma 
 
FH 
Hereditary 
leiomyomatosis 
Dominant HIF1 
Leiomyomas 
 
SDHB, C, D 
Familial 
paraganglioma 
Dominant HIF1 
Paragangliomas, 
pheochromocytoma
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s 
VHL 
Von Hippel–
Lindau 
syndrome 
Dominant HIF1 
Kidney 
 
TP53 (p53) 
Li-Fraumeni 
syndrome 
Dominant p53 
Breast, sarcoma, 
adrenal, brain 
WT1 
Familial 
Wilms tumor 
Dominant p53 
Wilms’ 
 
STK11 (LKB1) 
Peutz-Jeghers 
syndrome 
Dominant PI3K 
Intestinal, ovarian, 
pancreatic 
 
PTEN 
Cowden 
syndrome 
Dominant PI3K 
Hamartoma, 
glioma, uterine 
 
TSC1, TSC2 
Tuberous 
sclerosis 
Dominant PI3K 
Hamartoma, kidney 
 
CDKN2A 
(p16INK4A, p14ARF)  
Familial 
malignant 
melanoma 
Dominant RB 
Melanoma, 
pancreas 
 
CDK4 
Familial 
malignant 
melanoma 
 
Dominant RB Melanoma 
RB1 
Hereditary 
retinoblastoma 
Dominant RB 
Eye 
 
NF1 
Neurofibromat
osis type 1 
Dominant RTK 
Neurofiber 
 
BMPR1A 
Juvenile 
polyposis 
Dominant SMAD 
Gastrointestinal 
 
SMAD4 (DPC4) 
Juvenile 
polyposis 
Dominant SMAD Gastrointestinal 
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Oncogenes 
 
KIT Familial 
gastrointestinal 
stromal tumor 
Dominant RTK 
Gastrointestinal 
stromal tumor 
 
MET Hereditary 
papillary renal 
cell carcinoma 
 
Dominant RTK 
Kidney 
 
PDGFRA Familial 
gastrointestinal 
stromal tumor 
Dominant RTK 
Gastrointestinal 
stromal tumor 
 
 
RET 
 
Multiple 
endocrine 
Dominant RTK 
Thyroidal, 
parathyroida, 
adrenal 
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1.5.Apoptosis in cancer 
Apoptosis, programmed cell death, is a physiological process of cellular suicide that is 
integral to tissue homeostasis and is more feasibly observable during embryonic 
development, whereas at which stage more than 10 billion cells are made in the human 
body every day to balance those dying of apoptosis (Abud, 2004). It is characterized by a 
number of cellular morphological changes, such as cell shrinkage, membrane blebbing, 
organelle relocalization, nuclear fragmentation, chromatin condensation, and  the 
production of the ‘apoptotic bodies’, which are membrane-enclosed particles containing 
intracellular material (Kerr et al., 1972). Another pathway of cell death is “necrosis”, which 
lacks the features of apoptosis and autophagy. It could be differentiated from apoptosis by 
certain changes in cellular mechanisms and morphological characteristics, including 
dysfunctional organelles, collapsing mitochondria, ATP depletion, cellular swelling, and 
extreme cellular disintegration, all of which end up forming an inflammation in the cells. 
This is in contrast with apoptosis, which is not accompanied by any inflammation (Gerl & 
Vaux, 2005; Kerr et al., 1972). 
Triggering cells by apoptotic inducers, such as viral infections, bacterial toxins, free 
radicals, death ligands (like Fas), glucocorticoids, chemotherapeutics, radiation therapy, 
heat shock, growth factor withdrawal and/or irreparable DNA damage; makes many 
distinctive changes in the cells (Elmore, 2007). One of the distinguished families of 
proteins is called caspases. It plays a significant role in the initial stages of apoptosis. It 
breaks down the main components required for normal cellular functions, like the proteins 
which shape the cytoskeleton and the DNA repair enzymes. In addition, caspases induce 
the degradation enzymes, like DNases, leading to DNA cleavage in the nucleus (Song & 
Steller, 1999). The apoptotic process promotes different morphological changes that are 
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specific to the apoptotic cells. Mainly, cells shrink due to the cleavage of actin and laminin 
in the cytoskeleton, and the nuclei take on a "horse-shoe" shape because of the breakdown 
of their chromatin contents. As shrinking continues, the cells package themselves to 
become easy victims for removal by macrophages. Changes in the apoptotic cells’ 
membranes are responsible for triggering the macrophagal response  (Ghatage et al., 2012) 
 
Table 1.3 the differences between apoptosis and necrosis  
 
 
 
 
Apoptosis  Necrosis 
Physiologic, regulated 
Cell shrinkage 
Chromatin condensation 
Preservation of Intracellular organelles 
Membrane blebbing  
apoptotic bodies 
Organized chromatin  
Digestion to small fragments (‘DNA ladders’) 
Pathologic, unregulated 
Cell swelling 
Irregular chromatin 
Clumping, dysfunction and destruction of organelles 
Disruption of cellular membranes 
Non-specific and random degradation of DNA 
(‘DNA smears’) 
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1.5.1. Caspase family regulates apoptosis: 
 Caspases, which are cysteine-dependent, aspartate-specific proteases, are a family 
of enzymes that is vital for the initiation and execution of apoptosis (Earnshaw, Martins, & 
Kaufmann, 1999). They remain in their inactive proenzyme forms in most healthy cells; 
however, caspases’ action is irreversible once activated by death signals; because the 
protease cascade starts the initiation process, whereas the single-chain procaspases are 
driven into a breakdown mechanism at specific aspartic acid residues, whereby the 
inhibitory N-terminal pro-domain is removed to form the active proteases. Apoptotic 
caspases are divided into two types: the first one comprises the initiators, or “the upstream 
caspases”. They usually come with long pro-domains (>90 amino acid); and start the 
cascade such as caspase-2,-8,-9,-10. The second one comprises the effectors, or “the 
downstream caspases”. They come with short pro-domains, containing 20-30 residues, and 
play a major role in the cleavage processes that disassemble the cell. An example is 
caspase-3,-6,-7 (Thornberry & Lazebnik, 1998). Hence, the activation of an effector 
caspase, like caspase-3 or caspase-7, is achieved by an initiator caspase, such as caspase-9. 
However, this process requires many components, such as apoptosome, which is a protein 
complex responsible for the activation of caspase-9. The latter then activates caspase-3, 
leading to changes in morphology and biology in the apoptotic cell (Ghatage et al., 2012). 
1.5.2. Mechanism of apoptosis 
The mechanisms of apoptosis are highly complex and advanced processes. They 
make an energy-dependent cascade of molecular events. There are two main pathways of 
apoptosis: the intrinsic or the mitochondria-initiated apoptosis pathway, and the extrinsic or 
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death-receptor initiated apoptosis pathway (Igney & Krammer, 2002). However, there is an 
additional pathway, referred to as the perforin/granzyme pathway, which could induce 
programmed cell death via either granzyme B or granzyme A. All of the intrinsic, extrinsic, 
and granzyme B pathways lead to the execution pathway, which starts with the cleavage of 
caspase-3, leading to the morphological changes associated with apoptosis. On the other 
hand, the granzyme A pathway activates a parallel caspase-independent cell death pathway 
via single-strand DNA damage (Martinvalet et al., 2005). 
The intrinsic pathway acts directly on targets within the cell. It may be induced by 
many triggers, like DNA damage, hyperthermia, radiation, free radicals,  hypoxia and/or a 
viral infection (Abud, 2004), all of which could cause changes in the inner mitochondrial 
membrane and lead to the release of pro-apoptotic proteins, such as cytochrome C, 
Smac/DIABLO, AIF, Endo G and HtrA2/Omi, from the intermembrane space into the 
cytosol. Consequently, activation of caspase-3 starts and the execution pathway begins. The 
Bcl2 families play a primary role in mediating and controlling this process. The Bcl2 
family has 4 homologous (BH) domains, which might either be anti-apoptotic or pro-
apoptotic. The pro-apoptotic proteins in the cell include Cl-10, Bax, Bak, Bid, Bad, Bim, 
Bik, and Blk, which may be localized at different parts of the cell. The anti-apoptotic 
members of the Bcl2 family are Bcl2 and Bclxl. Bcl2 are localized completely within the 
intracellular membranes and in the cytosol (Ghatage et al., 2012). These protein are key in 
determining whether the cell must perform apoptosis or not as they regulate the release of 
cytochrome C from the mitochondria in a process labeled as mitochondrial outer membrane 
permeabilization (MOMP).This is accomplished by an interaction between pro-apoptotic 
Bcl2 and membrane pores and channels which might be accompanied by a loss of 
mitochondrial membrane potential (Saelens et al., 2004). When the pro-apoptotic Bcl2 units 
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are released from the inter-membrane spaces into the cytosol, the main caspase-dependent 
group, which comprises cytochrome c, Smac/DIABLO and HtrA2/Omi, works to induce 
the caspase cascade. It binds to and activates Apaf-1 and procaspse-9, leading to the 
formation of the apoptosomes, which result in the activation of caspase-9 and the effectors, 
caspase-3 and caspase-7; and this marks the end of the apoptotic pathway (Fulda & 
Debatin, 2004). 
 
The extrinsic Pathway is a rapid mechanism that results in apoptosis. It is a caspase-
dependent process which requires transmembrane receptor-mediated interactions, like the 
reactions between the ligands corresponding to the death receptors, including FasL/FasR, 
TNF-α/TNFR1, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5 (Ashkenazi & Dixit, 1998). 
After a ligand and a death receptor bind, the receptor changes its conformation (Abud, 
2004) allowing them to interact with specific intracellular adaptor proteins, leading to 
changes in the “death domain”; which is made up of an extracellular domain and a 
cytoplasmic domain, and plays an essential  role in transmitting the death signal from the 
surface of the cell to intracellular signaling pathways (Ashkenazi & Dixit, 1998). For 
example, TRADD, a TNFR-associated death domain, recruits many apoptotic proteins to 
the receptor, at which point, the protein complex formed is often called the Death-Inducing 
Signaling Complex (DISC). DISC results in the autocatalytic activation of caspase-8, and 
the initiation of apoptosis. Alternatively, FADD, a FAS-associated death domain, could 
form a link with TRADD, which would lead to the cleavage of pro-caspase 8, and the 
induction of apoptosis  (Kischkel et al., 1995; Wajant, 2002). 
 
The perforin/granzyme pathway is an extrinsic pathway used by cytotoxic T 
lymphocytes (CTLs) to kill specific cells, such as tumor and virus-infected cells (Brunner et 
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al., 2003). Its mechanism is based on the release of perforin, proteases granzyme A and 
granzyme B. The perforin units form transmembrane pore proteins in the attacked cells’ 
membranes (Trapani & Smyth, 2002). Thus, perforin proteins enable the entry of granzyme 
A and granzyme B, which are considered the main components inside the granules. 
Granzyme B units activate pro-caspase-10 and caspase-3, which results in the induction of 
apoptosis (Sakahira et al., 1998). On the other hand, granzyme A, also released by T cells, 
induces apoptosis via a caspase-independent mechanism as it indirectly activates a tumor 
suppressor gene product, an effect which is called DNA nicking. The expression of this 
product, known as DNAse NM23-H1, is diminished in cancer cells (Fan et al., 2003). The 
activation of NM23-H1 occurs by cleavage of the proteins which inhibits NM23-H1 inside 
of the SET complex. Hence, the activation process promotes the release of NM23-H1, 
causing DNA fragmentation (Lieberman & Fan, 2003) 
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Figure 1.3: Pathways of apoptosis 
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1.6.Colorectal carcinoma 
Colorectal carcinoma (CRC) is the term used to describe tumor formation in the large 
intestine, colon and/or the rectal area. It has the third highest incidence rate among all 
cancer types globally, preceded only by lung and breast cancers; and it is considered to be 
one of the leading causes of death among patients of both sexes. The  risk rises after the age 
of 50. However, it could be managed if detected early. (Gustin & Brenner, 2002). 
Specialists have divided colorectal cancer into four main stages in terms of the 
morbidity of the disease: Dukes’ A, B, C and D. This pathological staging system has been 
in use for more than 50 years. The first stage, Dukes' A, refers to a condition whereby 
contiguous lesions contiguous exist only in the innermost lining bowel wall of the colon or 
the rectum, without reaching the muscularis. Dukes’ B refers to cases in which the cancer 
penetrates the muscularis. Dukes' C describes conditions whereby the cancer has spread to 
the lymph nodes around the bowel area. Dukes' D stage is the most dangerous and death-
leading phase as cancer would have spread to other organs in the body, such as the lungs 
and/or the spleen (Dukes, 1932). 
Colon cancer is a multi-step disease. It occurs as a consequence of a series of 
pathological changes that transform normal epithelial cells of the colon into invasive 
carcinoma. Several studies have shown that the multi-step process of colon cancer is 
accompanied by certain mutations affecting the adenomatous polypsis coli (APC) gene and 
cyclooxygenase-2 (COX-2), as well as K-ras mutations (caused by Kirsten-rat sarcoma 
virus), loss of the 18q21 gene, microsatellite instability, mutations in the transforming 
growth factor-β II receptor (TGFβR2), and stabilization and translocation of β-catenin 
(Kanwar et al., 2010; Kobayashi et al., 2000) 
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1.7.Major signaling pathways in colon carcinogenesis 
1.7.1. Wnt /β-catenin signaling pathway 
Wnt (Wingless and INT-1) – which refers to a large family of secretory 
glycoproteins – signaling pathway has a significant role in embryogenesis, cell-to-cell 
signaling, and adult tissue homeostasis (Clevers, 2006). Wnt/β-catenin, which is considered 
the most important Wnt pathway, regulates the transcription of cofactor β-catenin, 
and, therefore, enhances the expression of its respective gene (Logan & Nusse, 2004). 
Abnormal Wnt/β-catenin signaling is a primary factor in the development of  
tumorigenesis, degenerative disorders, osteoporosis and aging (Moon et al.,  2004). It is 
well known that over 90% of colon cancer cases result from the accumulation of Wnt and 
β-catenin due to mutations of the APC tumor suppressor gene, or oncogenic mutations of β-
catenin (Giles et al.,  2003; Luu et al., 2004). An increase in the levels of β-catenin, a key 
component of the Wnt signaling pathway, has been observed in many types of human 
cancer, such as prostate cancer, colon cancer, melanoma, and breast cancer (Chien et al., 
2009; Luu et al., 2004). The Wnt /β-catenin complexes promote the expression of many 
oncogenes, like the c-Myc, cyclin D1 and MMP genes, which are essential for tumor 
angiogenesis and cancer development (Dihlmann & Doeberitz, 2005). Thus, compounds 
which target the Wnt signaling pathway and downregulate it could make for a potential 
treatment of cancer (Luu et al., 2004; Tetsu & McCormick, 1999).  
1.7.2. Notch Signaling Pathway 
Notch signaling plays a fundamental role in the development of normal cells and 
tissues, like those of the cardiovascular system, central nervous system, and endocrine 
system. Its role is also implicated in bone development and tissue renewal (Allenspach et 
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al., 2007). In addition, Notch is considered as a conserved cell signaling mechanism. It is 
associated with different effects on cellular processes, such as cell fate determination, 
differentiation, cell proliferation, programmed cell death (apoptosis), adhesion, epithelial-
mesenchymal transition, migration, and angiogenesis. Regulation of these processes can 
become faulty in Notch-mediated pathological situations (Artavanis-Tsakonas, Rand, & 
Lake, 1999; Bolós, Grego-Bessa, & de la Pompa, 2007). In mammals, there are four Notch 
proteins (Notch 1–4) and one Notch membrane-bound type 1 receptor with one 
transmembrane domain (Baron, 2003; Bolós et al., 2007).  Preclinical and clinical studies 
have attributed a pro-oncogenic function to Notch signaling in many solid tumors (Rizzo et 
al., 2008). An increase in the rate of Notch pathway signaling is associated with many kinds 
of cancers, such as melanoma and lung, breast, pancreas, renal and colon cancers (Collins 
et al., 2004; Strizzi et al., 2009). 
An in vivo study has demonstrated strong synergies between Notch and Wnt signals 
in colon cancer that result in the formation of intestinal adenomas and, more significantly, 
colorectal tumor (Fre et al., 2009; Hayward et al., 2008). Since Notch pathway is 
complicated, a better understanding of its interactions with other pathways is required for 
future therapeutic applications (Bolós et al., 2007; Rizzo et al., 2008). 
1.7.3. P53 signaling pathway    
The p53 tumor suppressor gene was identified in 1979. It performs an essential role 
in the activation of apoptosis and cell arrest pathways. It has been labeled as "the guardian 
of the genome" because of its role in preventing genome mutation (Fridman & Lowe, 2003; 
Read & Strachan, 1999) Activation of p53 by DNA damage, aberrant oncogene expression 
or hypoxia causes an induction in cell-cycle checkpoints, DNA repair, cellular senescence, 
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and apoptosis. Hence, disruption of this pathway or a mutation in p53  may end in 
checkpoint defects, genomic instability, inappropriate survival, cancer, neurodegeneration, 
ischemia, cholestasis and/or  atherosclerosis (Amaral et al., 2010). Many factors make p53 
gene mutation very prevalent in human malignancies. First of all, a single base change in 
the coding sequence results in a dysfunctioning P53. Secondly, a single abnormal p53 allele 
or allele loss can alter the phenotype of the p53 proteins. Thirdly, since p53 plays a role in 
multiple pathways, defects in its coding gene make the cell’s defenses completely 
diminished against carcinogenesis (Bellamy, 1997). 
It is well-established that any mutation in the p53 tumor suppressor gene causes its 
function to be lost, leading to profound proliferation of cancer cells and chemoresistance 
(Beroud & Soussi, 2003; Hussain & Harris, 1998; Wallace-Brodeur & Lowe, 1999). On the 
other hand, hyper-activation of p53 product has been associated with many different 
diseases, like arthritis, multiple sclerosis, and neuropathies (Mattson et al., 2001; Wosik et 
al., 2003). Moreover, in vivo studies have suggested that acute p53 activation is the 
mechanism behind the side effects of cancer chemotherapy (Komarova & Gudkov, 2001; 
Tyner et al., 2002). 
1.7.4. TGF-β Signaling Pathway 
TGFβ and its receptors are extensively expressed in all tissues; and  TGFβ signaling 
has a dual role in human diseases (Massagué, 1998). In cancer, TGFβ acts as both a tumor 
suppressor and an oncogene which promotes tumor metastasis (Katz et al., 2013). Its tumor 
suppressive effects, which are observed in the early stages of cancer and in normal cells, 
include an inhibition of cell proliferation, an induction of apoptosis, and an inhibition of 
cell immortalization. In contrast, the tumor promoting effects of TGFβ  include invasion, 
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migration, cell adhesion, tumor metastasis and an induction of Epithelial-Mesenchymal 
Transition (EMT), which has been observed in invasive and aggressive tumors  (Massagué, 
1998; Xu et al., 2009) . Furthermore, as a tumor progresses and increases in size, it secretes 
a huge amount of autocrine TGFβ, which gets released into the surrounding area. The 
increased levels of TGFβ affect the tumor and the vicinity, and promote 
immunosuppression and angiogenesis, inhibit cell adhesion, and promote the metastatic 
processes (Gorsch et al., 1992). Using antibodies to target the TGF-β proteins or receptors 
has shown a promising anticancer effect. However, the dual role of TGFβ translates into 
potential side effects for any novel compounds targeting this pathway (Massagué, 2008). 
1.7.5. Cell cycle (pRB/ E2F) signaling pathway 
The main element in this pathway is the retinoblastoma tumor suppressor protein 
(pRB), whose role is to induce apoptosis and inhibit cell cycle progression (Robert A 
Weinberg, 1995).  pRB stops premature G1/S transitions by physical interaction with 
several transcription factors, namely E2F, which is vital for the activation of the S-phase 
genes (Bartek et al.,  1996). It is believed that mutations in the Rb gene are present in the 
vast majority of human cancer conditions (Hunter, 2002). For example, such mutations 
have been detected in cases of osteosarcoma, small cell lung carcinoma, breast carcinoma 
and other cancer types (Nevins, 2001). In addition, a downregulated E2F activity has been 
reported in human tumor cases, and has been attributed to many mechanisms, such as a 
functional loss of pRB; amplification of cyclin D, a cyclin-dependent kinase inhibitor that 
inhibits the phosphorylation of pRB, which promotes the phosphorylation of pRB; a loss of 
p16; and an expression of E7, the human papillomavirus (HPV) oncoprotein, which 
disrupts the pRB–E2F complexes (Sherr & McCormick, 2002). 
